SeaStar Q3 Revenue Up 247% but NEUTRALIZE-AKI Enrollment Slips to Mid-2027
ICU is trading near its 52-week low of $1.84 (9.2% below the low).
Summary
SeaStar's Q3 revenue rose 247% to $635 thousand on QUELIMMUNE adoption, but the adult NEUTRALIZE-AKI trial enrollment slipped to mid-2027 and cash fell to $3.989 million before $3.3 million of October warrant proceeds.
Key Events · Earnings and Guidance · ICU
-
Q3 Revenue Jumps 247%
Net revenue was $635 thousand versus $183 thousand in Q3 2025, with gross margin above 90%; nine-month revenue reached $1.745 million and management expects to exceed its $2 million full-year guidance.
-
Adult Trial Enrollment Pushed to Mid-2027
NEUTRALIZE-AKI has enrolled 251 of 339 patients (~75%), but management now expects completion by mid-year 2027; the final PMA module is expected about nine months after enrollment closes.
-
Cash Falls to $3.989 Million
Cash dropped from $11.980 million at December 31, 2025 to $3.989 million at September 30, 2026, before $3.3 million of October warrant proceeds; nine-month operating cash burn was $9.128 million against a $4.529 million Q3 net loss.
-
PMA Modules Filed Early
The first module of a modular premarket approval application for the adult AKI indication has been submitted, with additional modules planned; Breakthrough Device Designation should enable priority review once the clinical module is filed.
Analysis · ICU · Industrial Applications And Services
Revenue growth is real — QUELIMMUNE sales of $635 thousand in Q3 are up 247% year over year at >90% gross margin — but the quarter's headline is the enrollment delay. Management pushed completion of the 339-patient NEUTRALIZE-AKI adult trial to mid-year 2027, and the final PMA module follows roughly nine months after that, so the adult AKI approval decision now looks like 2029 rather than 2028. Against that backdrop the balance sheet is thin: $3.989 million of cash at September 30, plus $3.3 million of October warrant proceeds, against a $4.529 million quarterly net loss and $9.128 million of cash burned in nine months. That is roughly two quarters of runway before another raise, and the company previously disclosed substantial doubt about its ability to continue as a going concern.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ICU was trading at $1.67 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $10.2M. The 52-week trading range was $1.84 to $5.38. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.